Skip to main content
. 2018 May 11;42(2):905–918. doi: 10.3892/ijmm.2018.3672

Figure 4.

Figure 4

BCL2L12 S156A and L213A mutants are involved in reactivation of apoptotic markers and drug-induced autophagy. (A) The expression profiles of p53 and of various apoptotic and autophagic markers were examined by western blotting. (B) Quantitative plot of relative cleaved PARP and p53 expression in U87MG cells with or without expression of BCL2L12 and its mutants (S156A or L213A). (C) Quantitative plot of relative expression of apoptotic markers cleaved PARP, cleaved caspase-3 and cleaved caspase-9 in U87MG cells with or without expression of BCL2L12 and its mutant proteins. (D) Quantitative plot of relative expression of autophagy-related proteins LC3B-I, II, ATG12-ATG5 conjugates and Beclin-1 in U87MG cells with or without expression of BCL2L12 and its mutant proteins. All target protein expression levels were normalized to β-actin expression prior to conversion into fold increase measurements. *P<0.05 and **P<0.01 compared with WT group. BCL2L12, BCL2-like 12; p53, tumor protein p53; PARP, poly-ADP-ribose-polymerase; LC3B, microtubule associated protein 1 light chain 3B; ATG, autophagy-related gene; STS, staurosporine; TMZ, temozolomide; GFP, green fluorescent protein; WT, wild-type.